185 related articles for article (PubMed ID: 21235734)
21. Free Energy of Binding and Mechanism of Interaction for the MEEVD-TPR2A Peptide-Protein Complex.
Lapelosa M
J Chem Theory Comput; 2017 Sep; 13(9):4514-4523. PubMed ID: 28723223
[TBL] [Abstract][Full Text] [Related]
22. Antiproliferative effect of HSP90 inhibitor Y306zh against pancreatic cancer is mediated by interruption of AKT and MAPK signaling pathways.
Xue N; Jin J; Liu D; Yan R; Zhang S; Yu X; Chen X
Curr Cancer Drug Targets; 2014; 14(7):671-83. PubMed ID: 25219422
[TBL] [Abstract][Full Text] [Related]
23. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
24. Definition of the minimal fragments of Sti1 required for dimerization, interaction with Hsp70 and Hsp90 and in vivo functions.
Flom G; Behal RH; Rosen L; Cole DG; Johnson JL
Biochem J; 2007 May; 404(1):159-67. PubMed ID: 17300223
[TBL] [Abstract][Full Text] [Related]
25. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.
Lundgren K; Zhang H; Brekken J; Huser N; Powell RE; Timple N; Busch DJ; Neely L; Sensintaffar JL; Yang YC; McKenzie A; Friedman J; Scannevin R; Kamal A; Hong K; Kasibhatla SR; Boehm MF; Burrows FJ
Mol Cancer Ther; 2009 Apr; 8(4):921-9. PubMed ID: 19372565
[TBL] [Abstract][Full Text] [Related]
26. Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead.
Meli M; Pennati M; Curto M; Daidone MG; Plescia J; Toba S; Altieri DC; Zaffaroni N; Colombo G
J Med Chem; 2006 Dec; 49(26):7721-30. PubMed ID: 17181154
[TBL] [Abstract][Full Text] [Related]
27. A native mass spectrometry platform identifies HOP inhibitors that modulate the HSP90-HOP protein-protein interaction.
Veale CGL; Mateos-Jiménez M; Vaaltyn MC; Müller R; Makhubu MP; Alhassan M; de la Torre BG; Albericio F; Mackay CL; Edkins AL; Clarke DJ
Chem Commun (Camb); 2021 Oct; 57(83):10919-10922. PubMed ID: 34591048
[TBL] [Abstract][Full Text] [Related]
28. X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response.
Zhao Z; Zhu J; Quan H; Wang G; Li B; Zhu W; Xie C; Lou L
Oncotarget; 2016 May; 7(20):29648-63. PubMed ID: 27105490
[TBL] [Abstract][Full Text] [Related]
29. The flavonoid TL-2-8 induces cell death and immature mitophagy in breast cancer cells via abrogating the function of the AHA1/Hsp90 complex.
Liu HJ; Jiang XX; Guo YZ; Sun FH; Kou XH; Bao Y; Zhang ZQ; Lin ZH; Ding TB; Jiang L; Lei XS; Yang YH
Acta Pharmacol Sin; 2017 Oct; 38(10):1381-1393. PubMed ID: 28504248
[TBL] [Abstract][Full Text] [Related]
30. Importance of the C-terminal domain of Harc for binding to Hsp70 and Hop as well as its response to heat shock.
Cartledge K; Elsegood C; Roiniotis J; Hamilton JA; Scholz GM
Biochemistry; 2007 Dec; 46(51):15144-52. PubMed ID: 18052042
[TBL] [Abstract][Full Text] [Related]
31. The heat shock protein 90 inhibitor, (-)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer progression model.
Moses MA; Henry EC; Ricke WA; Gasiewicz TA
Cancer Prev Res (Phila); 2015 Mar; 8(3):249-57. PubMed ID: 25604133
[TBL] [Abstract][Full Text] [Related]
32. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
Jensen MR; Schoepfer J; Radimerski T; Massey A; Guy CT; Brueggen J; Quadt C; Buckler A; Cozens R; Drysdale MJ; Garcia-Echeverria C; Chène P
Breast Cancer Res; 2008; 10(2):R33. PubMed ID: 18430202
[TBL] [Abstract][Full Text] [Related]
33. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
[TBL] [Abstract][Full Text] [Related]
34. Y-632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo.
Wang W; Liu Y; Zhao Z; Xie C; Xu Y; Hu Y; Quan H; Lou L
Cancer Sci; 2016 Jun; 107(6):782-90. PubMed ID: 27002306
[TBL] [Abstract][Full Text] [Related]
35. Overlapping sites of tetratricopeptide repeat protein binding and chaperone activity in heat shock protein 90.
Ramsey AJ; Russell LC; Whitt SR; Chinkers M
J Biol Chem; 2000 Jun; 275(23):17857-62. PubMed ID: 10751404
[TBL] [Abstract][Full Text] [Related]
36. The non-canonical Hop protein from Caenorhabditis elegans exerts essential functions and forms binary complexes with either Hsc70 or Hsp90.
Gaiser AM; Brandt F; Richter K
J Mol Biol; 2009 Aug; 391(3):621-34. PubMed ID: 19559711
[TBL] [Abstract][Full Text] [Related]
37. DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction.
Chen X; Liu P; Wang Q; Li Y; Fu L; Fu H; Zhu J; Chen Z; Zhu W; Xie C; Lou L
Cancer Lett; 2018 Oct; 434():70-80. PubMed ID: 30017966
[TBL] [Abstract][Full Text] [Related]
38. Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer.
Hyun SY; Le HT; Nguyen CT; Yong YS; Boo HJ; Lee HJ; Lee JS; Min HY; Ann J; Chen J; Park HJ; Lee J; Lee HY
Sci Rep; 2018 Sep; 8(1):13924. PubMed ID: 30224681
[TBL] [Abstract][Full Text] [Related]
39. The effect of celastrol, a triterpene with antitumorigenic activity, on conformational and functional aspects of the human 90kDa heat shock protein Hsp90α, a chaperone implicated in the stabilization of the tumor phenotype.
Zanphorlin LM; Alves FR; Ramos CH
Biochim Biophys Acta; 2014 Oct; 1840(10):3145-52. PubMed ID: 24954307
[TBL] [Abstract][Full Text] [Related]
40. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
